A recent study published in The Lancet Neurology demonstrates the accuracy of blood-based biomarkers in differentiating Alzheimer's disease from other neurodegenerative conditions. Conducted in Spain with 786 participants, the research analyzed proteins such as p-tau217, amyloid-β42/40 ratio, and neurofilament light chain (NfL) in blood samples. The findings suggest that plasma p-tau217, particularly when paired with other markers, could potentially reduce the need for invasive diagnostic methods, paving the way for easier and earlier testing in patients with cognitive concerns.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
